Interview: Dr Zan Fleming on pre-diabetes

If you are unable to see the message below, click here to view.

Dear buzzhairs  buzzhairs, To celebrate the launch of our new websites, Phacilitate are pleased to offer you the chance to download interviews from some of the thought leaders who will speak at the Metabolic Leaders' Forum 2013. You can download them free of charge here.

Interview with Dr Alexander Fleming, President & CEO, Kinexum, LLC  Dr Fleming discusses FDA's fairly recent decision to approve Qsymia and Belviq, as well as the ongoing development of Orexigen's Contrave. He also shares his thoughts on where the next wave of novel targets for obesity and T2DM will come from. Download the interview here  Alternatively, email us at team@phacilitate.co.uk and we will send you a copy of the interview

Interested to find out more?  Dr Fleming will be participating as a speaker at the Metabolic Leaders Forum 2013 in a discussion around the viability of pre-diabetes/metabolic syndrome as a target indication for pharma and biotech. If you wish to join Dr Fleming and numerous other decision makers from the metabolic space at the event this October, register here. Register before 2nd of August and save $500. Kind regards, David McCall Portfolio Director Phacilitate